Intraperitoneal Infusion Improves CAR-T Cell Therapy in Solid Tumor Models
In solid tumor models, intraperitoneal infusion improved CAR-T cell antitumor efficacy and persistence compared to standard intravenous delivery.
In solid tumor models, intraperitoneal infusion improved CAR-T cell antitumor efficacy and persistence compared to standard intravenous delivery.
A 2026 narrative review synthesizes evidence that inflammatory blood ratios, endothelial scores, and CAR-T-specific tools can stratify outcomes in hematologic ...
Engineered CAR-T cells equipped with a synthetic radiation-inducible promoter locally release tumor necrosis factor upon tumor irradiation to enhance antitumor ...
A new mathematical model comparing chemotherapy and CAR T-cell therapy for leukemia finds that simulated T-cell infusion produces a stronger ...
A new review maps how artificial intelligence could overcome resistance and safety barriers in cancer stem cell-targeted cellular immunotherapy, while ...
A case report describes how calcineurin inhibitor-free, mTOR-based immunosuppression enabled successful CD19 CAR T-cell therapy in a kidney-pancreas transplant recipient ...
Researchers report that the epigenetic regulator BAZ2A drives renal cancer cells to accumulate palmitic acid, which impairs CAR-T cell mitochondria ...
A new review in Blood Research outlines how early detection, risk prediction models, and phenotype-directed treatment are reshaping the management ...
An early study of 28 Korean DLBCL patients found that positive Deauville 4–5 findings on post-CAR T-cell PET/CT scans were ...
A new review explains how targeted immunotherapies are stripping predictive power from traditional risk markers in adult B-cell acute lymphoblastic ...
A new commentary in Cardio-Oncology marks 30 years since Daniela Cardinale coined the term cardio-oncology and presents the first English ...
A three-case report links residual CAR transgene at transplantation to persistent CAR-T donor cells causing mixed chimerism with cytopenia, with ...
A prospective single-center observational study found that patient-reported physical and functional burden after CAR T-cell therapy peaked during hospitalization and ...
A Hong Kong phase II trial of six children found that locally manufactured point-of-care CD19 CAR-T cells, produced in 14 ...
A retrospective study of 109 patients finds that CD19-directed CAR T-cell therapy reduces nodal and extranodal lymphoma tumors to a ...
A National Cancer Institute grant will fund planned OU trials testing whether opaganib can enhance CAR T-cell activity against ultra-high-risk ...
A retrospective cohort study of 96 patients shows the CAR-HEMATOTOX score predicts severe neutropenia and thrombocytopenia after CAR-T cell therapy, ...
Chimeric antigen receptor T cell therapy has redefined the treatment of multiple myeloma, offering deep and durable remissions to patients ...
A longitudinal study of 155 lymphoma patients found that older adults recovered memory function after CAR T-cell therapy while younger ...
New awards from the AACR, Department of Defense and National Cancer Institute will fund enhancer hub research, ovarian cancer immunotherapy, ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.